 In the early 2000s, the FDA's resources to screen DTC ads were not keeping pace with the number of ads being produced, raising the risk that the inappropriate ads were not removed.Vioxx was heavily marketed and was widely-prescribed after its approval in 1999.When the drug was withdrawn for safety reasons in 2004, Merck, its developer, and the FDA were criticized for the campaign.